LBCTR2022065051暂停3 期
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome - NEPTUNUS-2
ovartis Pharmaceuticals0 个研究点目标入组 5 人开始时间: 2024年3月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 暂停
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 至 99（—）
- 性别
- All
入选标准
- •Signed informed consent must be obtained prior to participation in the study
- •- Women and men = 18 years of age
- •- Classification of Sjögren's syndrome according to the ACR/EULAR 2016 criteria
- •- Time since diagnosis of Sjögren's of = 7.5 years at screening
- •Positive anti-Ro/SSA antibody at screening
- •Patients negative for anti-Ro/SSA antibody are eligible, if they have a positive salivary gland biopsy confirmed by central expert review
- •- Enrollment of anti-Ro/SSA-negative patients will be limited up to =10% of the study population
- •- Screening ESSDAI score of = 5 within the following 8 domains: constitutional, lymphadenopathy, glandular, articular, cutaneous, renal, hematological and biologic.
- •- Stimulated whole salivary flow (sSF) rate of = 0.05 mL/min at screening
- •- Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study
- •- Patients taking hydroxychloroquine (= 400 mg/day), methotrexate (= 25 mg/week) or azathioprine (= 150 mg/day) alone or in combination, are allowed to continue their medication, and must have been on a stable dose for at least 30 days prior to randomization.
- •- Patients taking systemic corticosteroids have to be on a stable dose of = 10 mg/day predniso(lo)ne or equivalent for at least 30 days before randomization.
- •- Patients taking
- •disease-modifying antirheumatic drugs (DMARDs) other than specifically allowed in inclusion criterion #9 or
- •the following Traditional Chinese Medicines: Total glucoside of peony (TGP) or Tripterium glycosides (TG)
- •- must discontinue these medications at least 30 days prior to randomization, except for leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a cholestyramine wash-out has been performed.
排除标准
- •- Presence of another autoimmune rheumatic disease that is active and constitutes the principal illness
- •- Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer3. Prior treatment with ianalumab
- •- Prior use of a B-cell depleting therapy other than ianalumab within 36 weeks prior to randomization or as long as B-cell count is <50 cells/µL
- •- Prior treatment with any of the following within 6 months prior to randomization:
- •iscalimab, belimumab , abatacept, anti-tumor necrosis factor alpha biologic agents, immunoglobulins plasmapheresis; i.v. or oral cyclophosphamide and mycophenolate mofetil, i.v. or oral cyclosporine A; any other immunosuppressants (e.g., JAK inhibitors or other kinase inhibitors) unless explicitly allowed by protocol
- •- Use of corticosteroids (predniso(lo)ne or equivalent corticosteroid) at dose >10 mg/day
- •- Any one of the following laboratory values at screening:
- •Hemoglobin levels < 8.0 g/dL
- •White blood cells (WBC) count < 2.0 x 10E3/µL
- •Platelet count < 80 x 10E3/µL
- •Absolute neutrophil count (ANC) < 0.8 x 10E3/µL
- •- Active viral, bacterial or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of bacterial infections with encapsulated organisms
- •- History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation (sucrose, L-histidine hydrochloride/ L-histidine, polysorbate 20)
- •- History of major organ, hematopoietic stem cell or bone marrow transplant
- •- Required regular use of medications known to cause dry mouth/eyes as a regular and major side effect, and which have not been on a stable dose for at least 30 days prior to Screening, or any anticipated change in the treatment regimen during the course of the study.
- •- Use of topical ocular prescription medications (excluding artificial tears, gels, lubricants) that have not been on a stable dose for at least 90 days prior to randomization, or any anticipated change in the treatment regimen during the course of the study
- •- Receipt of live/attenuated vaccine within a 4-week period prior to randomization
- •- History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV) test result
- •- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer or Sjögren's related lymphoma), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- •- History of sarcoidosis
- •- Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes mellitus), psychiatric or additional physical condition that the Investigator feels may jeopardize the patient in case of participation in this study
- •- Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). Positive serology for hepatitis B surface antigen (HBsAg) excludes the subject.
- •- Evidence of active tuberculosis (TB) infection (after anti-TB treatment, patients with history of or latent TB may become eligible according to national guidelines)
- •- Pregnant or nursing (lactating) women,
- •- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless the
研究者
相似试验
招募中
3 期
Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjogren's syndromeSjogren's SyndromeJPRN-jRCT2041220098Hirano Takamitsu36
进行中（未招募）
1 期
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients with Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlEUCTR2016-004889-26-HUSanofi-aventis Recherche & Développement1,800
进行中（未招募）
1 期
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients with Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlEUCTR2016-004889-26-ESSanofi-aventis Recherche & Développement1,800
进行中（未招募）
1 期
A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients with Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlType 2 diabetes mellitusChronic kidney disease stage 4MedDRA version: 20.0Level: LLTClassification code 10076411Term: Chronic kidney disease stage 4System Organ Class: 100000070575MedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-004906-32-ESSanofi-aventis Recherche & Développement277
进行中（未招募）
1 期
A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients with Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlType 2 diabetes mellitusChronic kidney disease stage 4MedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 23.1Level: LLTClassification code 10076411Term: Chronic kidney disease stage 4System Organ Class: 100000004857EUCTR2016-004906-32-ITSANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT277